Step‐wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: This study examined the relationship between the number of prior antidepressant treatment trials and step‐wise increase in pharmacodynamic tolerance (or progressive loss of effectiveness) in subjects with bipolar II depression. Methods: Subjects ≥18 years old with bipolar II depression (n=129) were randomized to double‐blind venlafaxine or lithium carbonate monotherapy for 12 weeks. Responders (n=59) received continuation monotherapy for six additional months. Results: After controlling for baseline covariates of prior medications, there was a 25% reduction in the likelihood of response to treatment with each increase in the number of prior antidepressant trials (odds ratio [OR]=0.75, unstandardized coefficient [B]=−0.29, standard error (SE)=0.12; χ 2=5.70, P<.02], as well as a 32% reduction in the likelihood of remission with each prior antidepressant trial (OR=0.68, B=−0.39, SE=0.13; χ 2=9.71, P=.002). This step‐wise increase in pharmacodynamic tolerance occurred in both treatment conditions. Prior selective serotonin reuptake inhibitor (SSRI) therapy was specifically associated with a step‐wise increase in tolerance, whereas other prior antidepressants or mood stabilizers were not associated with pharmacodynamic tolerance. Neither the number of prior antidepressants, nor the number of prior SSRI s, or mood stabilizers, were associated with an increase in relapse during continuation therapy. Conclusions: The odds of responding or remitting during venlafaxine or lithium monotherapy were reduced by 25% and 32%, respectively, with each increase in the number of prior antidepressant treatment trials. There was no relationship between prior antidepressant exposure and depressive relapse during continuation therapy of bipolar II disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Venlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Neumeister, A., Hu, X.-Z., Luckenbaugh, D. A., Schwarz, M., Nugent, A. C., Bonne, O., Herscovitch, P., Goldman, D., Drevets, W. C., & Charney, D. S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.9.978 · Cited by 161
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
Leykin, Y., Amsterdam, J. D., DeRubeis, R. J., Gallop, R., Shelton, R. C., & Hollon, S. D. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.267 · Cited by 82
Self-citationTachyphylaxis in unipolar major depressive disorder
Solomon, D. A., Leon, A. C., Mueller, T. I., Coryell, W., Teres, J. J., Posternak, M. A., Judd, L. L., Endicott, J., & Keller, M. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0302 · Cited by 71
Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., Li, S. Q., Mao, J. J., & DeRubeis, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.070 · Cited by 57
Self-citationSharma, V. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00212-3 · Cited by 54
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Self-citationZimmerman, M., & Thongy, T. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0814 · Cited by 31
Lieb, J., & Balter, A. (1984) · Medical Hypotheses · doi:10.1016/0306-9877(84)90018-5 · Cited by 30
Bonavita, C. D., Bisagno, V., Bonelli, C. G., Acosta, G. B., Rubio, M. C., & Wikinski, S. I. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00012-6 · Cited by 19
Cited by
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
“Prior exposure to ADMs and history of nonresponse to ADMs have each been found consistently to predict poor response to future courses of antidepressants (Amsterdam et al. 2009, 2016; Amsterdam & Shults 2009; Byrne & Rothschild 1998).”
BackgroundSelf-citationMore treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“This is of particular importance since a stepwise loss of antidepressant effectiveness with repeated antidepressant trials has been observed in BD-II (Amsterdam et al. 2016).”
BackgroundInfluentialFountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93
Self-citation
Metadata
- Authors
- Amsterdam, J. D., Lorenzo‐Luaces, L., & DeRubeis, R. J.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2016-11
- Volume
- 18
- Issue
- 7
- Pages
- 563-570
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2547845943
- Cited by
- 18
- References
- 13
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.